teva mylan adapt challeng gener industri
page full analyst note jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
found start small drug distributor
evolv contract manufactur penicillin tablet
dietari supplement later recogn manufactur
dyazid diuret prescrib drug unit state
time compani enter gener market
passag hatch-waxman act made
first acquisit manufactur parkinson drug drug
discoveri capabl sinc compani made
dozen acquisit includ matrix laboratori
current teva sandoz subsidiari novarti
account approxim half gener sale
europ balanc market highli fragment low-cost
manufactur grown rapidli activ compet
less differenti commod gener drug
regulatori hurdl lower european countri
compani gener revenu billion annual roughli
smaller closest competitor teva
lead global gener manufactur industri undergo
dramat chang also one
controversi publicli trade healthcar compani rapid
declin north american gener market price
pressur entri gener competit largest specialti
drug epipen treatment anaphylaxi food drug
administr warn letter one facil congression
alleg price goug epipen high debt load share
declin june high mylan share
affect much closest peer teva
like due smaller exposur north america lower debt
load slightli insul
gener launch advair complex respiratori drug copaxon
treatment multipl sclerosi recent progress
develop biosimilar gener manag close
limit transpar specialti pipelin
share previous elimin
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
regist netherland lead gener drugmak
roughli manufactur facil although compani
form compani posit second-largest gener
compani larg attribut acquisit matrix laboratori
gener busi germany-bas merck kgaa portfolio
gener specialti over-the-count activ
ingredi medicin
manufactur epipen treatment anaphylaxi acquir
merk kgaa transact
predominantli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
teva mylan adapt challeng gener
took fresh deep dive analysi teva
continu view compani moat
two controversi healthcar name batter
gener drug price pressur confluenc legal
matter concern high debt load market
backdrop made critic focu rapidli replenish
gener specialti pipelin aggress right size
infrastructur flex scale fend
intern competitor significantli lower cost
structur despit commod natur gener
need regulatori compliant cost-effect drug overal
expect compani trade base pipelin
progress opioid litig especi ohio abil
teva transpar activ
differenti focus specialti drug rel
complex manufactur gener fiscal
like trough year teva revenu new
specialti drug ajovi austedo off-set declin
blockbust specialti drug copaxon although
compani cost save initi continu launch
track well tweak fair valu estim
reflect slight shift cash flow time
also includ million litig settlement
teva fiscal expect total opioid litig
hover around billion estim level
manag allow compani gener
oper cash flow pay matur debt
like benefit near term wixela gener
advair gener copaxon gain traction howev
confid abil introduc complex new
therapi replenish pipelin beyond launch
think weigh margin previous
expect result lower fair valu
estim
fair valu estim per share impli fiscal
enterpris value/adjust ebitda multipl time
price-to-earnings debt leverag ratio time
fair valu estim reflect compani growth
challeng gener drug industri increas
mylan go concern hover around abil manag
deterior gener price captur growth
complex gener biosimilar pipelin pay debt
overal revenu anticip grow fiscal
larg due launch gener advair wixela gener
copaxon biosimilar understand one drug
repres revenu lack transpar
specialti gener revenu pose challeng
understand key driver busi
reflect signific improv fiscal
gross margin launch wixela gener advair
copaxon gain traction expect
compani sustain level expect gross margin
declin level fiscal oper
margin declin compani reinvest develop
pipelin previous anticip oper margin
increas fiscal level
believ achiev without
significantli replenish pipelin implement
notabl cost-sav initi confid
compani abil introduc complex new therapi
replenish matur pipelin beyond anticip fiscal
launch compani said one product
repres revenu detail beyond
rate firm high uncertainti rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oper expens overhead
believ possess econom moat
view gener drug predominantli no-moat industri
low barrier entri fill commoditylik
show lack price power lack moat
last sever year gener market contract
roughli perfect storm shape three
key market event show industri player lack
moat format three gener sourc group
yield signific negoti power account
approxim gener volum entri low-cost
manufactur mostli base india approv
abbrevi new drug applic file fda
allow multipl gener filer compet
gener convers rapidli shrink number potenti
gener sourc front
distributor larg pharmaci develop gener buy
consortium better negoti price manufactur
three largest gener sourc wbad claruson
red oak sourc gener volum chang
buy strategi negoti power shift favor
consortium addit market shift
indian govern encourag compani compet
intern although took year low-cost
manufactur garner share leverag
significantli lower oper expens structur
allow compet commod gener drug
sole price two factor critic drastic
deterior gener drug price direct low-cost
gener drug manufactur share grown significantli
still account small portion market
turn favor regulatori market gener
although launch wixela copaxon gener
variou biosimilar stabil gener busi
provid direct comfort compani abil
de-lever oper cash flow lack
visibl compani pipelin key driver inform
high uncertainti rate
part valuat framework addit
base-cas dcf also model bull bear case
valuat scenario critic debat
surround abil grow pipelin gener drug
continu scale oper
bull-cas fair valu estim per share
scenario abl grow overal revenu slightli
faster inflat slight declin
oper margin continu declin specialti
bear-cas fair valu estim per share
scenario assum compani replenish
pipelin off-set matur gener drug oper
margin anticip declin inabl scale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
probabl maintain share current market
increas competit dynam like make
challeng gener signific return
approv congress pass gener
drug user fee amend gdufa gdufa ii speed
approv new gener drug implement
regul signific increas
approv increas number gener drug
promot entri signific number gener
manufactur certain regul also implement
allow multipl gener filer compet within
exclus period hurt profit
addit extern market factor directli affect
incur signific debt acquir
dozen compani sinc fiscal
billion debt roughli time adjust ebitda
also notabl oper legal
issu includ govern prosecut epipen price
goug market opioid product well fda
letter requir remedi morgantown west
virginia facil factor includ entri gener
epipen competit weigh share
declin substanti sinc peak june
warrant stabl moat trend rate despit
factor caus signific deterior gener
market superior cost/regulatori structur mix
shift toward biosimilar enabl support
addit offset challeng
industri global scale vertic
integr provid low-cost edg highli fragment
market firm control world
gener product low-cost manufactur grown
rapidli compet
commod gener drug regulatori
hurdl lower european countri although
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
one world largest gener compani
enjoy economi scale smaller
ocompar peer less-diversifi
oper increas exposur volatil gener
oth acquisit agila meda enhanc
inject over-the-counter drug product
sustain steadier growth profit
develop complex gener drug
includ biosimilar gener version advair
copaxon
face consider competit low-cost
oth lack transpar pipelin key
driver increasingli competit market creat
credibl gap may deter investor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
mylan credit profil challeng larg debt
use acquisit oper compani
difficult growth trajectori increas gener price
competit loss market exclus epipen
expect revenu growth fiscal stabil
gener price launch wixela gener advair
introduct biosimilar manag said expect
aggress turnaround fiscal revenu growth
increas profit reflect
expect howev assum limit growth
beyond current year due lack pipelin
transpar result also assum
deterior oper margin inabl scale
competit market
adjust free
gener
gener revolv adjust
commit
lack visibl
assign mylan high uncertainti rate due
high geograph product concentr
addit
compani
pipelin mylan oper evolv healthcar market
signific regulatori competit pressur
need continu aggress replenish
pipelin complex gener specialti drug pay
debt howev challeng lack
visibl compani pipelin continu focu
complex gener critic remain lead gener
drug manufactur compet
manufactur teva
intern competitor larg debt balanc
abl pay oper cash flow
long pend state feder litig
accus
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
believ current manag team warrant
standard stewardship rate mani manag
strateg initi past year bolster
compani oper
integr manufactur capabl hard-to-manufactur
product howev think high take-over multipl larg
amount financi leverag slow integr
process acquir busi hamper potenti
acquisit inject manufactur agila becam
cloud compani receiv fda warn letter
manufactur qualiti concern critic price
increas epipen led neg media attent
settlement depart justic
improp classif drug medicaid rebat
compar peer consid execut pay
significantli averag includ person aircraft
use company-provid automobil larg portion
execut compens tie adjust earn per
share good measur long-term valu
creation view
heather bresch compani nearli
year becam ceo earli robert couri
ceo sinc transit execut chairman
bresch couri presid rajiv malik retir harri
korman repres four compani insid
board multist civil investig potenti price
collus among gener manufactur target malik
remain execut board role time
mark parrish replac rodney piatt lead
independ director vice chairman board parrish
board member sinc current
chairman ceo trident provid mobil x-ray
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
reduc confid abil achiev prior
assign mylan no-moat stabl trend rate
also lower fair valu estim per share
confid compani abil
introduc complex new therapi replenish pipelin
beyond anticip fiscal launch think
weigh margin previous expect
lead global gener manufactur industri
undergo dramat chang also one
controversi publicli
compani rapid gener market declin due
price pressur entri gener competit
largest specialti drug epipen treatment anaphylaxi
 food drug administr warn letter one
facil congression alleg price goug
epipen high debt load share declin
june high approxim mylan share
affect much closest peer teva
like due smaller exposur north america
lower debt load slightli
insul gener launch advair complex
respiratori drug copaxon treatment multipl
sclerosi recent progress develop biosimilar
mylan global scale vertic integr provid
firm low-cost edg highli fragment market
firm control world gener
product teva sandoz subsidiari novarti
account approxim half gener sale
 europ balanc market highli
fragment low-cost manufactur grown rapidli
activ compet less differenti commod
gener drug regulatori hurdl lower
european countri although compani
probabl maintain share current market increas
competit dynam like make challeng
gener drug compani hit legal challeng
state file price-fix lawsuit
feder court sever gener drug manufactur
includ teva expect major
chang fair valu estim base legal action
potenti rang outcom fairli larg
difficult predict continu rate teva
uncertainti rate high extrem respect
partli relat high debt level firm carri
increas legal concern stem litig
announc support larger uncertainti
around fair valu estim compani
continu believ compani
moat given high degre competit key
core alleg lawsuit revolv around collus
set higher-than-norm price expect
lengthi trial ensu later year typic gener
drug fairli commodit product price
erod result competit rel easili
move market depend demand
price howev regul play role keep
firm market longer normal food
drug administr need approv new gener drug
sever year ago backlog gener drug file
fda delay new entrant would expect
gener firm use regulatori process complex
manufactur drug raw suppli issu
rational chang gener drug price overal
expect major chang drug price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
normal ep came slightli expect
overal revenu soft larg driven lower-than-
expect volum partial due time issu advers
foreign currenc exchang rate lesser degre
price competit pressur appear let
includ uptak challeng due payor prefer
brand drug despit re-affirmed guidanc time
new product launch share intra-day due
manag re-affirmed full-year revenu earn
free cash flow guidanc billion billion
billion billion respect
maintain no-moat rate fair valu estim
skeptic
back-end
manag indic necessari approv
grant help pave way toward billion
new product revenu target fiscal million
record first quarter new product
revenu target consist product launch carryov
launch wixela gener form respiratori drug
advair launch first quarter new product
launch occur throughout year net debt tick
due recent product
invest
manag confirm track achiev
leverag ratio time year-end fiscal first
quarter revenu declin year year billion
normal ep declin year year
normal ebitda margin declin last
although encourag progress new
product launch overal manag tone seem
cautiou still would exercis caution name
mani move part concern
back-end load guidanc
place review transfer coverag
new analyst expect publish new fair valu
estim second quarter
post disappoint fourth quarter
plan lower fair valu estim
perform although number recent product launch
like fulphila biosimilar neulasta wixela gener
advair help keep forecast billion revenu
year near midpoint guidanc adjust
ep estim fall high end manag
goal although expect
margin pressur gener competit epipen
on-going price pressur
 market
manag see higher market expens
anticip part sell effort
necessari compani complex product well
higher tax rate specul part higher cost
also stem warn letter receiv fourth
quarter morgantown manufactur facil
decent success beat competitor
market complex gener product includ
product like gener copaxon challeng reinforc
no-moat rate compani peer
mylan fourth-quart revenu declin year
ago stem declin north america
revenu off-set posit growth intern market
share gain gener copaxon late approv
gener advair morgantown remedi issu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ration gener portfolio amid competit
price pressur anticip price
stabil gener market
imagin mani factor stay persist
headwind addit complex
gener launch help uphold sale gross margin
becom expens endeavor sell
product market share gain slow
adjust ep rel flat year
manag outlook year suggest
earn declin midpoint
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
